Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
Abstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-021-00335-3 |
| _version_ | 1818693650095276032 |
|---|---|
| author | Takahiro Einama Yoji Yamagishi Yasuhiro Takihata Takafumi Suzuki Tamio Yamasaki Yuichi Hirose Kazuki Kobayashi Naoto Yonamine Ibuki Fujinuma Takazumi Tsunenari Makiko Koga Yusuke Ishibashi Ken Nagata Takehiro Shiraishi Akiko Nakazawa Toshimitsu Iwasaki Eiji Shinto Kimi Kato Kimiya Sato Hideki Ueno Yoji Kishi Hitoshi Tsuda |
| author_facet | Takahiro Einama Yoji Yamagishi Yasuhiro Takihata Takafumi Suzuki Tamio Yamasaki Yuichi Hirose Kazuki Kobayashi Naoto Yonamine Ibuki Fujinuma Takazumi Tsunenari Makiko Koga Yusuke Ishibashi Ken Nagata Takehiro Shiraishi Akiko Nakazawa Toshimitsu Iwasaki Eiji Shinto Kimi Kato Kimiya Sato Hideki Ueno Yoji Kishi Hitoshi Tsuda |
| author_sort | Takahiro Einama |
| collection | DOAJ |
| description | Abstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox’s multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer. |
| first_indexed | 2024-12-17T13:17:03Z |
| format | Article |
| id | doaj.art-7b3927c09b9c40ca8c025b518145e18f |
| institution | Directory Open Access Journal |
| issn | 2050-7771 |
| language | English |
| last_indexed | 2024-12-17T13:17:03Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj.art-7b3927c09b9c40ca8c025b518145e18f2022-12-21T21:46:58ZengBMCBiomarker Research2050-77712021-10-01911410.1186/s40364-021-00335-3Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patientsTakahiro Einama0Yoji Yamagishi1Yasuhiro Takihata2Takafumi Suzuki3Tamio Yamasaki4Yuichi Hirose5Kazuki Kobayashi6Naoto Yonamine7Ibuki Fujinuma8Takazumi Tsunenari9Makiko Koga10Yusuke Ishibashi11Ken Nagata12Takehiro Shiraishi13Akiko Nakazawa14Toshimitsu Iwasaki15Eiji Shinto16Kimi Kato17Kimiya Sato18Hideki Ueno19Yoji Kishi20Hitoshi Tsuda21Department of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery Basic Pathology, National Defense Medical CollegeDepartment of Surgery Basic Pathology, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery Basic Pathology, National Defense Medical CollegeAbstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox’s multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer.https://doi.org/10.1186/s40364-021-00335-3Breast cancerMesothelinCA125/MUC16Co-expression |
| spellingShingle | Takahiro Einama Yoji Yamagishi Yasuhiro Takihata Takafumi Suzuki Tamio Yamasaki Yuichi Hirose Kazuki Kobayashi Naoto Yonamine Ibuki Fujinuma Takazumi Tsunenari Makiko Koga Yusuke Ishibashi Ken Nagata Takehiro Shiraishi Akiko Nakazawa Toshimitsu Iwasaki Eiji Shinto Kimi Kato Kimiya Sato Hideki Ueno Yoji Kishi Hitoshi Tsuda Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients Biomarker Research Breast cancer Mesothelin CA125/MUC16 Co-expression |
| title | Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients |
| title_full | Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients |
| title_fullStr | Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients |
| title_full_unstemmed | Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients |
| title_short | Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients |
| title_sort | co expression of mesothelin and ca125 muc16 is a prognostic factor for breast cancer especially in luminal type breast cancer patients |
| topic | Breast cancer Mesothelin CA125/MUC16 Co-expression |
| url | https://doi.org/10.1186/s40364-021-00335-3 |
| work_keys_str_mv | AT takahiroeinama coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT yojiyamagishi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT yasuhirotakihata coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT takafumisuzuki coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT tamioyamasaki coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT yuichihirose coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT kazukikobayashi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT naotoyonamine coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT ibukifujinuma coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT takazumitsunenari coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT makikokoga coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT yusukeishibashi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT kennagata coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT takehiroshiraishi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT akikonakazawa coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT toshimitsuiwasaki coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT eijishinto coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT kimikato coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT kimiyasato coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT hidekiueno coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT yojikishi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients AT hitoshitsuda coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients |